European Medicines Agency Recommends Approval Of Adapted Nuvaxovid Covid-19 Vaccine Targeting Omicron XBB.1.5 Dated October 31, 2023
Portfolio Pulse from Benzinga Newsdesk
The European Medicines Agency has recommended the approval of an adapted version of the Nuvaxovid Covid-19 vaccine, developed by Novavax, which targets the Omicron XBB.1.5 variant.
October 31, 2023 | 4:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Novavax's adapted Nuvaxovid vaccine targeting the Omicron XBB.1.5 variant has been recommended for approval by the EMA. This could potentially boost the company's revenues and stock price.
The recommendation for approval of Novavax's adapted Nuvaxovid vaccine by the EMA is a positive development for the company. This could lead to increased sales of the vaccine, especially in Europe, and potentially boost the company's revenues and stock price. However, the final impact will depend on the actual approval and subsequent market acceptance of the vaccine.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100